Antabio SAS, Biostep, 436 rue Pierre et Marie Curie, 31670 Labège, France.
Department of Microbiology and Immunology, Rollins Research Center, 1510 Clifton Rd, Atlanta, Georgia 30322, United States.
ACS Infect Dis. 2023 Feb 10;9(2):270-282. doi: 10.1021/acsinfecdis.2c00418. Epub 2023 Jan 20.
LasB elastase is a broad-spectrum exoprotease and a key virulence factor of , a major pathogen causing lung damage and inflammation in acute and chronic respiratory infections. Here, we describe the chemical optimization of specific LasB inhibitors with druglike properties and investigate their impact in cellular and animal models of infection. Competitive inhibition of LasB was demonstrated through structural and kinetic studies. LasB inhibition was confirmed with respect to several host target proteins, namely, elastin, IgG, and pro-IL-1β. Furthermore, inhibition of LasB-mediated IL-1β activation was demonstrated in macrophage and mouse lung infection models. In mice, intravenous administration of inhibitors also resulted in reduced bacterial numbers at 24 h. These highly potent, selective, and soluble LasB inhibitors constitute valuable tools to study the proinflammatory impact of LasB in infections and, most importantly, show clear potential for the clinical development of a novel therapy for life-threatening respiratory infections caused by this opportunistic pathogen.
LasB 弹性蛋白酶是一种广谱外切蛋白酶,也是导致肺部损伤和炎症的主要病原体 (一种引起急性和慢性呼吸道感染的关键毒力因子)。在这里,我们描述了具有类药性的特定 LasB 抑制剂的化学优化,并研究了它们在细胞和动物感染模型中的影响。通过结构和动力学研究证明了对 LasB 的竞争性抑制。通过对几种宿主靶蛋白(即弹性蛋白、IgG 和 pro-IL-1β)的研究,证实了对 LasB 的抑制作用。此外,在巨噬细胞和小鼠肺部感染模型中也证明了抑制 LasB 介导的 IL-1β 激活。在小鼠中,静脉给予抑制剂也导致 24 小时时细菌数量减少。这些高效、选择性和可溶性的 LasB 抑制剂是研究 LasB 在感染中的促炎作用的有价值的工具,最重要的是,为治疗由这种机会性病原体引起的危及生命的呼吸道感染的新型疗法的临床开发展示了明确的潜力。